Cannabis Science, Inc. (OTC Bulletin Board: CBIS), a pioneering US
biotech company developing pharmaceutical cannabis products, is pleased
to announce the partnership with The Unconventional Foundation for
Autism (UF4A) to build on the Foundation's success with its proprietary
cannabinoid formulations for Autism treatment. The partnership will
focus on advancing the medical cannabis treatments for Autism in
conjunction with the successful cannabis treatments of Joey and 10 other
families that are now being documented by The University of California
Irvine Medical Center (UCI) for the Foundation.
These successful Autism treatments and pioneering efforts of Joey's Mom,
Mieko Hester Perez, can be fully reviewed at www.uf4a.org.
Mieko and the successful treatment of her son has garnered wide-spread
media interest including television appearances and interviews with KABC
7 - Los Angeles & San Francisco, 20/20 ABC, Good Morning America, Fox
Morning News, Fox News Rhode Island, CBS Early Show, KCAL 9 & CBS 2 Los
Angeles, The Doctor's TV Show, KABC 790 w/ Peter Tilden, Montel
Williams, The Tom Joyner Show, The Kim Frasier Show w/ Dr. Lester
Grinspoon, The Bill Press Show, NORML's Podcast w/ Russ Belville,
Thomasina Tafur radio show. Featured interviews: Autism Spectrum
Magazine, Treating yourself Magazine, Huffington Post, Autism Spot,
Celebstoner, disability scoop, Autism Support Network, Kush Magazine
August 2010 Issue Cover, High Times Medical Marijuana Magazine Winter
2011 Issue, Treating yourself Magazine (Joey's sibling interviewed Issue
#23, Weed World UK Issue #89, Now Magazine UK Publications, Medical
Cannabis Journal Issue, LA JEMM - Ethical Use of Medical Marijuana in
the Treatment of Children with Autism, Orange County Register,
California, The Revolution - Argentina publication. 2010 Recognized by
the National Organization to Reform Marijauna Laws Woman's Alliance as
one of the woman making history in the medical marijuana movement.
Mieko Hester Perez, Founder and Executive Director of The Unconventional
Foundation for Autism (UF4A) stated, ?We believe that this new
partnership with Cannabis Science will give us additional push and
resources required to advance our Autism research. To date, we have
already partnered with the University of California Irvine Medical
Center to oversee our cannabis-based Autism research. Included in this
group of advisors is the Dean of Medicine at UCI, and child psychiatrist
Dr. Rebecca Hedrick M.D. Dr. Melamede of Cannabis Science will be an
outstanding addition to the Board of the Foundation. His extensive
knowledge of cannabinoid science should prove invaluable in our mission.?
As part of the new partnership, Dr. Robert Melamede, CEO of Cannabis
Science, will be joining the board of UF4A as a scientific advisor. Dr.
Melamede will work with UF4A to further assist in documenting the case
studies and oversee the deployment of the Company's proprietary
cannabinoid treatments on Autism patients alongside UF4A and medical
professionals. He will also work with UF4A's legal advisors to progress
the legalization of medical marijuana initiatives.
Dr. Robert Melamede Ph.D., Cannabis Science Inc., President & CEO,
stated, ?Cannabis Science's partnership with UF4A is another
instrumental step in reaching our long-term goal of FDA approval of the
Company's products. The successful results from the Autism patients
treated as documented by UF4A are very encouraging and we're excited to
tap into UF4A's proven track record; providing our scientific expertise
to help develop more refined treatment plans with Cannabis Science's
formulations and extracts to achieve scientifically accepted patient
outcomes. I'm also extremely excited to be working with the medical
professionals at the University of California Irvine. This is a win-win
for both our organizations in breaking new ground for medical cannabis
treatments. Our partnership will enable both our Company and UF4A to
expound upon studies and anecdotal evidence obtained by UF4A in order to
catalogue verified case studies and solid science behind the treatment
plans. This evidentiary step will help the UF4A and Cannabis Science
partnership to move towards formal FDA testing to officially approve
UF4A's successful treatments of Autism using medical cannabinoid
extracts and formulations under the direction of physicians. ?
UF4A Case Studies
Mieko Hester-Perez and her son ?Joey? have inspired many additional
parents with autistic children to step forward. Studies are underway
with these children with oversight from Child & Adolescent Psychiatrist
Dr. Rebecca M. Hedrick, M.D.
Dr. Hedrick is a child and adolescent emergency attending physician and
covers the consult liaison service at UCI Medical. She runs a child and
adolescent outpatient psychotherapy and medication management program.
She also works with the Regional Center of Orange County in the
treatment of individuals with developmental disabilities.
Associate Training Director, Psychiatry & Human Behavior School of
Medicine M.D., Phone: (714) 456-8775 Fax: (714) 456-7605 Email: rhedrick@uci.edu
About UF4A
The Unconventional Foundation for Autism, UF4A for short, is a
non-profit organization. The mission of UF4A is three fold: (1) to raise
awareness and support for families afflicted with this mysterious and
misunderstood condition known as Autism; (2) to raise funds for
cannabis-based medical research and clinical trials; and (3) to campaign
for a rescheduling of cannabis from Schedule 1 narcotic (no accepted
medical benefits) to a lower schedule so that the appropriate research
may be conducted, and so that all patients have access to medication. A
listing on Schedule 1 is tantamount to a research blockade and, frankly,
is unacceptable where millions continue to needlessly suffer and subject
to criminal punishment should they choose to use cannabis under the
direction of their physician. The Schedule 1 listing fails to reflect
the prevailing medical view that cannabis has accepted medical benefits.
UF4A is quickly becoming a leading advocate in the fight for nationwide
investigation, research and analysis of the legalization of Medical
Marijuana.
The partnership promises to advance the innovative medical autism
research headed by Executive Director Mieko Hester- Perez. The
Unconventional Foundation Autism's partnership focus is to bridge the
gap between parents, scientists, and medical professionals to provide a
better quality of life for our children diagnosed with the misunderstood
condition known as Autism.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade
medical marijuana research and development. The Company works with world
authorities on phytocannabinoid science targeting critical illnesses,
and adheres to scientific methodologies to develop, produce and
commercialize phytocannabinoid-based pharmaceutical products. In sum, we
are dedicated to the creation of cannabis-based medicines, both with and
without psychoactive properties, to treat disease and the symptoms of
disease, as well as for general health maintenance.
Forward Looking Statements
Forward Looking Statements; This Press Release includes forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Act of 1934. A statement
containing works such as "anticipate," "seek," intend," "believe,"
"plan," "estimate," "expect," "project," "plan," or similar phrases may
be deemed "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events or
results anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include the
future U.S. and global economies, the impact of competition, and the
Company's reliance on existing regulations regarding the use and
development of cannabis-based drugs. Cannabis Science, Inc. does not
undertake any duty nor does it intend to update the results of these
forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
info@cannabisscience.com
www.cannabisscience.com
1-888-889-0888
or
Mark
J. Friedman
Investor Relations
info@cannabisscience.com
www.cannabisscience.com
1-877-431-CBIS
(2247)
